SCHEDULE: Jorey Chernett Discloses 9.45% Stake in OKYO Pharma

Jorey Chernett has filed an amended Schedule 13G, disclosing a 9.45% beneficial ownership stake in OKYO Pharma Ltd.

Summary

• Jorey Chernett, an individual, has filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in OKYO Pharma Ltd.
• Chernett beneficially owns 3,802,194 shares of Common stock in OKYO Pharma Ltd.
• This ownership represents 9.45% of the class of securities.
• Chernett holds sole voting power and sole dispositive power over all 3,802,194 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about OKYO Pharma Ltd.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's operations or financial performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors who acquire more than 5% of a company's stock, indicating a significant, non-controlling ownership position. This filing signals Jorey Chernett's continued substantial stake in OKYO Pharma Ltd.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual shareholder's stake, which could be viewed as a vote of confidence or a potential source of future influence, particularly concerning nominations.

Key Dates

Keywords

OKYO Pharma Ltd, Jorey Chernett, Schedule 13G, Beneficial Ownership, Equity Stake, Common Stock, SEC Filing, Shareholder Disclosure